Article
KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
Tumori - 1 Jan 2000
Battaglia Paolo, Baritono Elisabetta, Remo Andrea, Vendraminelli Roberto, Conti Antonio
Abstract excerpt
BACKGROUND: Screening for colorectal cancer (CRC) requires non-invasive methods of high diagnostic sensitivity and specificity. We evaluated the measurement of genetic and protein biomarkers of CRC in stool samples with the aim of testing their clinical utility in a CRC screening program. PATIENTS AND METHODS: Individuals aged 53-75 years who were at risk of CRC and immunochemical fecal occult blood test (iFOBT)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.